[HTML][HTML] In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - nature.com
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - pubmed.ncbi.nlm.nih.gov
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - ideas.repec.org
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - europepmc.org
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
[HTML][HTML] In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - ncbi.nlm.nih.gov
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - ui.adsabs.harvard.edu
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - econpapers.repec.org
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
M Kiso, Y Furusawa, R Uraki, M Imai… - Nature …, 2023 - search.ebscohost.com
Nirmatrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro), is
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
clinically useful against infection with SARS-CoV-2 including its omicron variants. Since …
[引用][C] In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
M Kiso, Y Furusawa, R Uraki, M Imai - Nature Communications, 2023 - europepmc.org
To characterize mutant viruses possessing amino acids mutations that are responsible for
reduced sensitivity to nirmatrelvir, we prepared a wild-type delta (B. 1.617. 2) variant and its …
reduced sensitivity to nirmatrelvir, we prepared a wild-type delta (B. 1.617. 2) variant and its …